NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Linda Pearson who wrote (329)	2/1/1999 4:53:00 PM
From: RCMac	of 613

>>I didn't find any article on Scios in the Wall Street Journal, let alone one that isn't upbeat. Maybe you can provide the article for those of us who are curious why you are slamming the stock.<< The article on SCIO, on page B5 of my WSJ, notes the FDA panel recommendation of approval of Natrecor, but goes on: " . . . but some analysts consider its sales prospects limited." . . . "Several analysts said Natrecor will face tough sledding in a market already filled with treatment options." Not exactly upbeat. Especially in light of the observation about CEPH's and other biotech's post-approval declines that TexasDude was responding to, his comment hardly seems like "slamming" the stock. -- RCM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next